WO2026142600 - A CAPSULE FORMULATION OF LISDEXAMFETAMINE DIMESYLATE
National phase entry is expected:
Publication Number
WO/2026/142600
Publication Date
02.07.2026
International Application No.
PCT/TR2025/051314
International Filing Date
17.10.2025
Title **
[English]
A CAPSULE FORMULATION OF LISDEXAMFETAMINE DIMESYLATE
[French]
FORMULATION EN CAPSULE DE DIMÉSILATE DE LISDEXAMFÉTAMINE
Applicants **
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Inventors
SUNEL, Fatih
ATAK, Fadime Bilgehan
ATAMAN, Seval
BENGUL, Furkan
Priority Data
2024/020286
24.12.2024
TR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
Turkpatent
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1993 | |
| EPO | Filing, Examination, Granting | 9318 | |
| Japan | Filing, Examination, Granting | 2083 | |
| South Korea | Filing, Examination, Granting | 1899 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,033
Contact Us
Abstract[English]
The present invention relates to a capsule formulation comprising lisdexamfetamine dimesylate and at least one filler, wherein filler is calcium phosphate dibasic anhydrous. Furthermore, the invention discloses a process which is simple, rapid, cost effective, time-saving and industrially convenient process and is created to eliminate the disadvantages of active ingredient.[French]
La présente invention concerne une formulation en capsule comprenant du dimésilate de lisdexamfétamine et au moins un excipient, ledit excipient étant du phosphate de calcium dibasique anhydre. En outre, l'invention divulgue un procédé simple, rapide, économique, permettant un gain de temps et industriellement commode, conçu pour éliminer les inconvénients du principe actif.